Given the heterogeneity of TNBC revealed by molecular profiling (Lehmann et al., 2011; Mayer et al., 2014), the general applicability of STAT3 signaling in cancer cells provides an alternative strategy to traditional chemotherapy. Here, STAT3 is linked to cancer.